Collecting duct carcinoma and renal medullary carcinoma in the age of new therapies

被引：0

作者：

Guillaume, Zoe ^{[1
]}

Allory, Yves ^{[2
]}

Auclin, Edouard ^{[1
]}

Gervais, Claire ^{[1
]}

Auvray, Marie ^{[1
]}

Rochand, Adrien ^{[1
]}

Mejean, Arnaud ^{[1
]}

Audenet, Francois ^{[1
]}

Vano, Yann-Alexandre ^{[1
]}

Oudard, Stephane ^{[1
]}

Thibault, Constance ^{[1
]}

机构：

[1] Univ Paris, Europeen Georges Pompidou Hosp, F-75020 Paris, France

[2] Inst Curie, St Cloud, France

来源：

BULLETIN DU CANCER | 2023年 / 110卷 / 04期

关键词：

Collecting duct carcinoma; Renal medullary carcinoma; Antiangiogenic TKI; Immunotherapy; GEMCITABINE PLUS PLATINUM; PHASE-II; COMPLETE RESPONSE; KIDNEY; BEVACIZUMAB; COMBINATION; BELLINI; CARBOPLATIN; PACLITAXEL; SUNITINIB;

D O I：

10.1016/j.bulcan.2023.02.015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Collecting duct carcinoma (also known as Bellini tumour) and renal medullary carcinoma are two extremely rare and aggressive renal cancers. They are both less responsive to conventional treatments used in clear cell renal carcinoma. There are very few studies evaluating their optimal management and currently, at the metastatic stage, polychemotherapy based on platinum salts remains the most widely used. The emergence of new treatments such as anti-angiogenic TKIs, immunotherapy or treatments targeting specific genetic abnormalities, opens up a new field of possibilities in the management of these cancers. The evaluation of the response to these treatments is therefore essential. In this article, we will review the status of their management and the various studies that have evaluated recent treatments in these two cancers.

引用

页码：450 / 462

页数：13

共 63 条

[1] Characteristics and Outcomes of Tumors Arising From the Distal Nephron [J].

Abern, Michael R. ;

Tsivian, Matvey ;

Polascik, Thomas J. ;

Coogan, Christopher L. .

UROLOGY, 2012, 80 (01) :140-146

[2] Topoisomerase II α Status in Renal Medullary Carcinoma: Immuno-Expression and Gene Copy Alterations of a Potential Target of Therapy [J].

Albadine, Roula ;

Wang, Wenle ;

Brownlee, Noel A. ;

Toubaji, Antoun ;

Billis, Athanase ;

Argani, Perdram ;

Epstein, Jonathan I. ;

Garvin, A. Julian ;

Cousi, Rima ;

Schaeffer, Edward M. ;

Pavlovich, Christian ;

Netto, George J. .

JOURNAL OF UROLOGY, 2009, 182 (02) :735-740

[3]

Albiges L, 2020, J CLIN ONCOL, V38

[4] Renal medullary carcinoma and sickle cell trait: A systematic review [J].

Alvarez, Ofelia ;

Rodriguez, Maria M. ;

Jordan, Lanetta ;

Sarnaik, Sharada .

PEDIATRIC BLOOD & CANCER, 2015, 62 (10) :1694-1699

[5]

[Anonymous], CARACTERISTIQUES CAN

[6]

[Anonymous], 2020, RECOMMANDATIONS FRAN

[7]

[Anonymous], 2013, ANAL SPATIALES, P80

[8] Phase II Study of Gemcitabine, Carboplatin, and Bevacizumab in Patients With Advanced Unresectable or Metastatic Urothelial Cancer [J].

Balar, Arjun V. ;

Apolo, Andrea B. ;

Ostrovnaya, Irina ;

Mironov, Svetlana ;

Iasonos, Alexia ;

Trout, Alisa ;

Regazzi, Ashley M. ;

Garcia-Grossman, Ilana R. ;

Gallagher, David J. ;

Milowsky, Matthew I. ;

Bajorin, Dean F. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06) :724-730

[9] Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma [J].

Bratslavsky, Gennady ;

Gleicher, Stephanie ;

Jacob, Joseph M. ;

Sanford, Thomas H. ;

Shapiro, Oleg ;

Bourboulia, Dimitra ;

Gay, Laurie M. ;

Elvin, Julie Andrea ;

Vergilio, Jo-Anne ;

Suh, James ;

Ramkissoon, Shakti ;

Severson, Eric Allan ;

Killian, Jonathan Keith ;

Schrock, Alexa Betzig ;

Chung, Jon H. ;

Miller, Vincent A. ;

Mollapour, Mehdi ;

Ross, Jeffrey S. .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (06) :367.e1-367.e5

[10] HER2 Blockade in Metastatic Collecting Duct Carcinoma (CDC) of the Kidney: A Case Report [J].

Bronchud, Miguel H. ;

Castillo, Sergi ;

Escriva de Romani, Santiago ;

Mourelo, Santiago ;

Fernandez, Alejandra ;

Baena, Cecilia ;

Murillo, Jesus ;

Julia, Joan C. ;

Esquius, Jordi ;

Romero, Ruben ;

Andreu, Xavier .

ONKOLOGIE, 2012, 35 (12) :776-779

← 1 2 3 4 5 6 7 →